Although mutations in IDH1, TP53 and ATRX were the most frequent in both groups, their mutation frequencies in the PDCL3 low group were higher than those in the PDCL3 high group, which also illustrated, at least in part, that PDCL3 may promote malignant progression and lead to poor prognosis in glioma patients. This evidence concerns the gene PDCL3 and glioma.